1311410-86-2

Upstream product

• 4654-39-1 4-bromophenethanol 
• 4248-19-5 tert-butyl carbazate 
• 27200-79-9 p-bromophenylacetaldehyde 
• 873-55-2 sodium benzenesulfonate 

Downstream Products

• 1606138-26-4 C₁₆H₂₂BrNO₃ 
• 1606138-27-5 C₁₆H₂₂BrNO₃ 
• 1606138-28-6 tert-butyl (2R,3R)-1-(4-bromophenyl)-3-methyl-4-oxobutan-2-ylcarbamate 
• 1606138-40-2 C₁₆H₂₂BrNO₃ 
• 1311412-27-7 C₂₄H₃₁N₃O₄ 
• 1311412-23-3 C₂₄H₃₃N₃O₅ 
• 1311411-98-9 C₃₀H₃₄FN₂O₆^(1-)*Na⁽¹⁺⁾ 
• 1311411-97-8 C₂₄H₂₈BrFNO₅^(1-)*Li⁽¹⁺⁾ 
• 1311411-93-4 C₄₀H₄₆F₂N₄O₆ 
• 1311411-91-2 C₄₆H₆₀F₂N₄O₆Si 
• 1311411-90-1 C₃₉H₅₁BrF₂N₂O₆Si 
• 1311411-88-7 C₃₅H₃₉FN₄O₄ 
• 1311411-86-5 C₄₀H₄₇FN₄O₆ 
• 1311411-84-3 C₃₃H₃₈BrFN₂O₆ 

Relevant academic research and scientific papers

Mechanistic studies of highly enantio-and diastereoselective aza-petasis-ferrier rearrangement catalyzed by chiral phosphoric acid

The precise mechanism of the highly anti-and enantioselective aza-Petasis-Ferrier (APF) rearrangement of hemiaminal vinyl ethers catalyzed by a chiral phosphoric acid was investigated by undertaking experimental and theoretical studies. The APF rearrangem

5-AMINO- 4-HYDROXYPENTOYL AMIDES

HIV inhibitors of formula (I) wherein R1 is halo, C1-4alkoxy, trifluoromethoxy; R2 is a group of formula (A); R3 is a group of formula (B); R4 is a group of formula (C); n is 0 or 1; A is CH or N; R5 and R6 are hydrogen, C1-4alkyl, halo; R7 and R8 are C1-4alkyl or C1-4alkoxyC1-4alkyl; R9 is C1-4alkyl, cyclopropyl, trifluoromethyl, C1-4alkoxy, or dimethylamino; R10 is hydrogen, C1-4alkyl, cyclopropyl, trifluoromethyl, C1-4alkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.